We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Neil
Bulstrode
Neil.Bulstrode@gosh.nhs.uk
Dr
Neil
Bulstrode
Neil.Bulstrode@gosh.nhs.uk
Other disorders of the skin and subcutaneous tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Countless scars occur annually from burns, surgical interventions, and trauma. Some scars can impact psychosocial functioning with increased anxiety and self-consciousness, and impair physical functioning and quality of life. Patient-reported outcomes (PROs), such as these, are well captured with PRO measures (PROMs). Recently, we developed and validated the SCAR-Q, a PROM specifically designed to capture a patient’s viewpoint about their scars, for both adult and pediatric (8 years of age and older) burn, surgical, and traumatic scar populations.
We are now in the later phases of instrument development and validation – establishing the responsiveness of the SCAR-Q, and determining the minimal important change (MIC), and minimal clinically important difference (MCID) in SCAR-Q scores. As an aspect of construct validity, responsiveness is how an instrument responds to change over time, and is a measurement standard for PROMs. The MIC is the smallest change in score perceived as important to a patient, while the MCID is the smallest difference in a measurable clinical parameter that indicates a meaningful change in the condition as perceived by the patient, clinician, or investigator. Assessing responsiveness and the MIC/MCID will be the primary aims of this study. Secondarily, our study will determine how scores on the SCAR-Q relate to scores on other commonly employed measures of scar assessment (e.g. Vancouver Scar Scale (VSS), and Patient and Observer Scar Assessment Scale (POSAS)); and also evaluate the influence of body image on scar perception as measured by the Body Esteem Scale for Adolescents and Adults (BESAA).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
Patients will be considered ineligible for the study if they fulfill any of the following criteria: • Are less than 8 years of age, • Do not speak and/or read English, • Have cognitive or developmental delay
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by THE HOSPITAL FOR SICK CHILDREN (Canada) and funded by PEDIATRIC DERMATOLOGY RESEARCH ALLIANCE, INC. .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48307
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
